Post Marketing Surveillance Study to Evaluate the Tolerability of Rebif® New Formulation in Patients With Relapsing Multiple Sclerosis in an Australian Clinical Setting.

NCT01101776 · clinicaltrials.gov ↗

COMPLETED

Status

49

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Interferon beta-1a (Rebif)

Sponsor

Merck KGaA, Darmstadt, Germany

Collaborators

[object Object]